Mogamulizumab

BIOLOGICAL20 trials

Sponsors

European Organisation For Research And Treatment Of Cancer, Aichi Medical University, Kyowa Kirin, Inc., Osaka University, National Cancer Institute (NCI)

Conditions

Adult T-Cell Lymphoma/LeukemiaAdvanced Solid TumorsCancerCarcinomaCutaneous T Cell LymphomaCutaneous T-Cell LymphomaCutaneous T-Cell Lymphoma RefractoryCutaneous T-Cell Lymphoma, Relapsed

Phase 1

Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.

Aichi Medical UniversitySolid Tumor

Start: 2013-02-28Target: 58Updated: 2016-02-17

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

CompletedNCT02301130

Kyowa Kirin, Inc.Advanced Solid Tumors

Start: 2014-11-26End: 2018-03-05Updated: 2024-04-25

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

CompletedNCT02358473

Kyowa Kirin, Inc.Non-Small Cell Lung Cancer

Start: 2015-01-31End: 2016-12-31Updated: 2024-09-19

KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

CompletedNCT02867007

Kyowa Kirin, Inc.Cancer, Carcinoma, Solid Tumor

Start: 2016-08-31End: 2019-12-15Updated: 2024-04-25

Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

CompletedNCT02946671

Osaka UniversityEsophageal Cancer, Gastric Cancer, Lung Cancer +2

Start: 2016-03-31End: 2020-03-31Updated: 2020-03-06

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

CompletedNCT03309878

National Cancer Institute (NCI)Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma +3

Start: 2018-10-24End: 2023-04-11Updated: 2023-09-21

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

CompletedNCT04185220

National Cancer Institute (NCI)Adult T-Cell Lymphoma/Leukemia, Mycosis Fungoides, Sezary Syndrome

Start: 2020-02-26End: 2022-05-18Updated: 2023-01-04

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

TerminatedNCT04541017

National Cancer Institute (NCI)Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome +9

Start: 2021-04-06End: 2024-10-24Updated: 2025-10-16

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

TerminatedNCT04676087

Emory UniversityMycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome

Start: 2021-04-21End: 2023-10-11Updated: 2024-08-13

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

RecruitingNCT04848064

John ReneauRecurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma +1

Start: 2022-05-06End: 2027-01-30Target: 12Updated: 2026-02-10

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

RecruitingNCT05414500

University of Alabama at BirminghamCutaneous T Cell Lymphoma, Mycosis Fungoides

Start: 2023-05-01End: 2026-07-31Target: 10Updated: 2025-08-08

Phase 2

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma

RecruitingNCT04128072

European Organisation for Research and Treatment of Cancer - EORTCStage IB-IIB Cutaneous T-Cell Lymphoma

Start: 2023-03-07End: 2027-01-31Target: 43Updated: 2024-04-05

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

RecruitingNCT04256018

Stanford UniversityMycosis Fungoides, Sezary Syndrome

Start: 2020-03-30End: 2026-12-31Target: 30Updated: 2025-07-02

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Active, not recruitingNCT04745234

Kyowa Kirin, Inc.Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed

Start: 2021-08-16End: 2025-05-31Updated: 2024-04-25

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

RecruitingNCT04930653

City of Hope Medical CenterFolliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome +5

Start: 2022-10-19End: 2028-06-15Target: 34Updated: 2025-10-14

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

RecruitingNCT05956041

University of Michigan Rogel Cancer CenterCutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome

Start: 2023-12-06End: 2027-04-30Target: 23Updated: 2026-01-07

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

RecruitingNCT05996185

Yale UniversityT-cell Lymphoma, T Cell Lymphoma

Start: 2024-10-09End: 2027-11-30Target: 22Updated: 2025-12-24

EORTC 1820-CLTF: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)

RecruitingCTIS2022-502434-10-00

European Organisation For Research And Treatment Of Cancera category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and Sézary Syndrome (SS))

Start: 2022-02-22Target: 37Updated: 2025-06-25

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

RecruitingNCT06698003

Memorial Sloan Kettering Cancer CenterLymphoma, T-cell Leukemia, T-cell Leukemia/Lymphoma +1

Start: 2024-11-15End: 2029-11-15Target: 134Updated: 2026-03-05

Phase 4

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Active, not recruitingNCT06285370

Kyowa Kirin China Pharmaceutical Co., Ltd.Cutaneous T-Cell Lymphoma

Start: 2023-05-29End: 2025-11-13Updated: 2025-09-18

Related Papers

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

2026-01-16

A phase I dose-finding study of mogamulizumab in combination with brentuximab vedotin in previously treated mycosis fungoides and Sézary syndrome

Blood2025-11-03

A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)

Blood2025-11-03

First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors

Cancer2025-06-194 citations

Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors

Journal for ImmunoTherapy of Cancer2025-04-014 citations

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood2024-11-05

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Blood Neoplasia2024-11-02

Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma.

2022-12-157 citations

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies

Blood Advances2022-04-2719 citations

Depletion of central memory CD8<sup>+</sup> T cells might impede the antitumor therapeutic effect of Mogamulizumab.

2021-12-1437 citations

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

Blood2021-11-053 citations

Rationale for the Clinical Use of Less Frequent Dosing of Mogamulizumab for T-Cell Lymphomas Using Population Pharmacokinetic and Exposure Response Analysis

Blood2021-11-05

443 Open-label, phase 2 study to assess the safety of mogamulizumab at 2 mg/kg Q4W maintenance dosing in patients with relapsed/refractory MF/SS subtypes of CTCL

Regular and Young Investigator Award Abstracts2021-11-01

Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies

Journal for ImmunoTherapy of Cancer2021-04-0143 citations

287 Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2020-11-013 citations

Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study

Clinical Cancer Research2020-06-2560 citations

A phase I and randomized phase II etctn study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in relapsed and refractory diffuse large B-cell lymphoma.

Journal of Clinical Oncology2020-05-204 citations

IL-15 in the Combination Immunotherapy of Cancer.

2020-05-19183 citations

First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2018-05-2013 citations

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Journal for ImmunoTherapy of Cancer2016-06-0229 citations